tiprankstipranks
Trending News
More News >
SSY Group Limited (HK:2005)
:2005

SSY Group (2005) AI Stock Analysis

Compare
2 Followers

Top Page

HK

SSY Group

(OTC:2005)

Rating:72Outperform
Price Target:
HK$3.00
▲(0.67%Upside)
SSY Group's stock is supported by solid financial performance and attractive valuation, making it appealing for value and income investors. However, technical analysis indicates limited momentum, and cash flow challenges could pose risks if not addressed. The absence of significant earnings call data and corporate events means these factors do not influence the score.

SSY Group (2005) vs. iShares MSCI Hong Kong ETF (EWH)

SSY Group Business Overview & Revenue Model

Company DescriptionSSY Group Limited, established in 2005, is a leading pharmaceutical company based in China. The company is primarily engaged in the research, development, manufacture, and sale of a wide range of pharmaceutical products. SSY Group operates in sectors including healthcare and pharmaceuticals, with core products such as intravenous infusion solutions, small-volume injections, and oral preparations. The company is known for its strong focus on innovation and quality, catering to both domestic and international markets.
How the Company Makes MoneySSY Group makes money through the production and sale of its pharmaceutical products. The company generates revenue by distributing its wide array of products, such as intravenous infusion solutions and small-volume injections, to hospitals, healthcare institutions, and pharmacies. Additionally, SSY Group benefits from its investment in R&D, which allows it to continually introduce new and improved products, thus expanding its market share. The company also leverages strategic partnerships and collaborations within the industry to enhance its distribution network and increase its reach, contributing to its overall revenue growth.

SSY Group Financial Statement Overview

Summary
SSY Group is financially solid with strong profitability and a stable balance sheet. The Income Statement and Balance Sheet are strong, with scores of 78 and 82, respectively, reflecting efficient operations and financial stability. However, cash flow management shows challenges, with a lower score of 65 due to fluctuating Free Cash Flow and a declining Free Cash Flow to Net Income ratio.
Income Statement
78
Positive
SSY Group has demonstrated strong profitability with a consistent Gross Profit Margin around 50% and improving Net Profit Margin, reaching 21.9% in 2023. Revenue growth has been steady, though it slightly declined from 2022 to 2023. The EBIT and EBITDA margins have remained healthy, reflecting efficient operations.
Balance Sheet
82
Very Positive
The company maintains a solid financial position with a Debt-to-Equity Ratio around 0.5, indicating moderate leverage. Return on Equity is robust, showcasing effective use of equity to generate profits. The Equity Ratio is strong at over 50%, reflecting stability and financial health.
Cash Flow
65
Positive
SSY Group's cash flow management shows challenges, with fluctuating Free Cash Flow and a declining Free Cash Flow to Net Income ratio. Operating Cash Flow has been positive, but the absence of recent data limits a comprehensive assessment.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
5.77B6.46B6.43B5.36B4.26B
Gross Profit
2.91B3.62B3.44B3.04B2.58B
EBIT
1.34B1.64B1.36B903.79M687.16M
EBITDA
1.74B2.11B1.86B1.40B1.09B
Net Income Common Stockholders
1.06B1.32B1.12B785.53M611.97M
Balance SheetCash, Cash Equivalents and Short-Term Investments
1.29B1.62B1.76B1.73B1.51B
Total Assets
12.60B11.97B10.97B10.71B9.25B
Total Debt
3.64B3.37B3.21B3.11B2.44B
Net Debt
2.38B1.76B1.50B1.41B984.62M
Total Liabilities
5.07B4.70B4.26B4.11B3.24B
Stockholders Equity
7.22B6.93B6.21B6.22B5.65B
Cash FlowFree Cash Flow
-49.39M221.88M368.70M359.58M236.61M
Operating Cash Flow
491.03M925.75M786.82M747.91M527.64M
Investing Cash Flow
-521.76M-640.19M-412.77M-681.23M-287.58M
Financing Cash Flow
-295.42M-304.57M-219.30M136.13M318.57M

SSY Group Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.98
Price Trends
50DMA
2.95
Positive
100DMA
3.04
Negative
200DMA
3.33
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
53.99
Neutral
STOCH
72.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2005, the sentiment is Positive. The current price of 2.98 is above the 20-day moving average (MA) of 2.90, above the 50-day MA of 2.95, and below the 200-day MA of 3.33, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 53.99 is Neutral, neither overbought nor oversold. The STOCH value of 72.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2005.

SSY Group Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
HK$9.67B9.6723.28%4.89%12.70%9.91%
75
Outperform
HK$5.65B6.2011.61%7.44%-18.09%-15.08%
73
Outperform
HK$1.85B3.0218.33%5.12%-9.95%67.56%
72
Outperform
$8.62B8.1514.96%5.87%-10.67%-19.27%
70
Outperform
HK$9.37B8.808.89%4.78%4.91%-11.80%
54
Neutral
$5.37B3.35-45.10%2.79%16.77%-0.01%
51
Neutral
$10.82B-4.93%2.69%-0.11%-290.77%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2005
SSY Group
2.98
-1.43
-32.44%
HK:0719
Shandong Xinhua Pharmaceutical Company Limited Class H
6.39
1.23
23.84%
HK:2877
China Shineway Pharmaceutical Group Limited
7.84
0.30
3.98%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
1.24
0.15
13.76%
HK:1681
Consun Pharmaceutical Group Ltd.
11.62
6.32
119.08%
HK:0460
Sihuan Pharmaceutical Holdings Group
1.16
0.65
127.45%

SSY Group Corporate Events

SSY Group Expands Ophthalmic Product Line with New Approval
Jun 9, 2025

SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of Timolol Maleate Eye Drops in unit dose packaging. This marks the company’s first approval of this kind in China and is part of its strategy to expand its ophthalmic product line. The new product is designed to effectively reduce intraocular pressure in various types of glaucoma, enhancing SSY Group’s position in the pharmaceutical market and potentially opening new sales channels by the end of the year.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group Gains Approval for New Drug Production
Jun 4, 2025

SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of two chemical drugs: Calcium Gluconate and Sodium Chloride Injection, and Potassium Chloride Granules. These approvals mark a significant step in the company’s product development, enhancing its portfolio in treating conditions such as acute hypocalcemia and hypokalemia, which could strengthen its market position and offer new opportunities for growth.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$5.20 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group Reports Decline in Q1 2025 Financial Performance
May 30, 2025

SSY Group Limited announced a significant decline in its unaudited operating results for the first quarter of 2025, with a 36.9% decrease in turnover compared to the same period in 2024. The drop in sales volume of intravenous infusion solutions and ampoule injections contributed to a 50.6% decrease in gross profit and a 59.5% decrease in profit attributable to shareholders. This downturn in financial performance could impact the company’s market positioning and stakeholder confidence.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group’s Dialysis Solution Gains Regulatory Approval
May 28, 2025

SSY Group Limited has announced that its Low Calcium Peritoneal Dialysis Solution has passed the Consistency Evaluation of the Quality and Efficacy of Generic Drugs by the National Medical Products Administration of China. This development marks a significant advancement for the company, enhancing its product offerings in the treatment of renal failure and potentially strengthening its position in the pharmaceutical market.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group Gains Approval for New Pharmaceutical Products in China
May 21, 2025

SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of two drugs: Dronedarone Hydrochloride Tablets and Gabexate Mesylate for Injection. These approvals mark significant advancements in the company’s product offerings, with Dronedarone Hydrochloride targeting atrial fibrillation and Gabexate Mesylate addressing acute pancreatitis. This development enhances SSY Group’s position in the pharmaceutical market, potentially benefiting stakeholders by expanding the company’s portfolio and market reach.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group Limited Successfully Concludes 2025 AGM with Key Resolutions Passed
May 16, 2025

SSY Group Limited held its Annual General Meeting (AGM) in 2025, where all proposed resolutions were passed. Key decisions included the re-election of executive directors, the re-appointment of KPMG as the auditor, and the approval of a final dividend. The meeting also granted the board of directors mandates to issue and repurchase shares, reflecting strong shareholder support and potentially impacting the company’s future financial strategies.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group’s Riluzole Gains Approval for Market Use in China
May 15, 2025

SSY Group Limited has announced that its drug Riluzole has received approval from the National Medical Products Administration of China for market use as a bulk drug. This development is significant as Riluzole is used to extend the life of patients with amyotrophic lateral sclerosis (ALS) or delay the need for mechanical ventilation. The approval marks a crucial step in SSY Group’s product development, potentially enhancing its market position and offering new treatment options for ALS patients.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$5.20 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group’s Lornoxicam Gains Approval in China
Apr 29, 2025

SSY Group Limited has announced that its product, Lornoxicam, has received approval from the National Medical Products Administration of China for registration as a bulk drug. This development marks a significant step in the company’s product offerings, potentially enhancing its market position in the pharmaceutical industry by expanding its portfolio of pain management solutions.

SSY Group’s Allopurinol Gains Approval for Market Release
Apr 28, 2025

SSY Group Limited has announced that its product, Allopurinol, has received approval from the National Medical Products Administration of China to be marketed as a bulk drug. This development marks a significant step in the company’s product offerings, particularly in the treatment of gout and high uric acid, potentially enhancing its position in the pharmaceutical market.

SSY Group Expands Pharmaceutical Portfolio with New Approvals
Apr 22, 2025

SSY Group Limited has received approvals from the National Medical Products Administration of China for the production and registration of new pharmaceutical products, including Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets and Ibuprofen Arginine Granules. These developments are expected to enhance the company’s product offerings in diabetes management and pain relief. Additionally, the company has obtained registration approvals for Acipimox and Diprophylline as bulk drugs, which will support their market presence in treating hyperlipidemia and respiratory conditions.

SSY Group Limited Announces Key Resolutions for Upcoming AGM
Apr 16, 2025

SSY Group Limited has announced its upcoming annual general meeting scheduled for May 16, 2025, in Hong Kong. Key agenda items include the adoption of the company’s financial statements for the year ending December 31, 2024, re-election of directors, and the re-appointment of KPMG as auditors. Additionally, a final dividend of HK$0.095 per share is proposed, and resolutions concerning the issuance of additional shares will be considered. These decisions are crucial for maintaining the company’s governance structure and financial strategies, potentially impacting shareholder value and market positioning.

SSY Group’s Felodipine Gains Approval in China
Apr 9, 2025

SSY Group Limited announced that its Felodipine drug has received approval from the National Medical Products Administration of China for market preparations, marking a significant step in its product development. This approval is expected to enhance the company’s market position in the pharmaceutical industry, particularly in China, and could have positive implications for shareholders and investors.

SSY Group Advances SYN045 Tablets to Phase I Clinical Trials
Apr 3, 2025

SSY Group Limited has announced the approval of its SYN045 tablets for Phase I clinical trials by the National Medical Products Administration of China. The approval includes three different specifications, which will enhance the clinical application and dosing precision of the drug. SYN045, a PGI2 receptor agonist, has shown promising results in preclinical studies with good targeting selectivity and safety, marking a significant step forward in the company’s drug development efforts.

SSY Group Secures Approval for New Injectable Drugs
Mar 31, 2025

SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of two new injectable drugs: Nicardipine Hydrochloride Injection and Sodium Bicarbonate Injection. These approvals mark significant progress in the company’s product development, enhancing its portfolio in emergency and metabolic treatment solutions, potentially strengthening its market position and offering new opportunities for growth.

SSY Group Gains Approval for Arbidol Hydrochloride Tablets
Mar 31, 2025

SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of Arbidol Hydrochloride Tablets, a drug used to treat various viral infections including influenza and coronavirus-related illnesses. This approval marks a significant step in the company’s product development, potentially enhancing its market position and offering new treatment options for respiratory infections.

SSY Group Limited Reports 2024 Annual Results Amid Challenging Market Conditions
Mar 28, 2025

SSY Group Limited faced a challenging business environment in 2024, marked by sluggish economic recovery and intensified trade protectionism. Despite these challenges, the company maintained stable development by focusing on innovation and optimizing its product mix. The company reported a revenue of approximately HK$5,773 million, a decrease of 10.7% from the previous year, and a net profit of HK$1,061 million, down by 19.5%. The company declared a final dividend of HK$0.095 per share, with a total dividend for the year increasing by 2.9%.

SSY Group Announces Final Dividend for 2024
Mar 28, 2025

SSY Group Limited has announced a final ordinary cash dividend of HKD 0.095 per share for the financial year ending December 31, 2024. The dividend will be paid on June 3, 2025, following shareholder approval on May 16, 2025. This announcement reflects the company’s financial performance and commitment to returning value to shareholders, potentially enhancing its market position and investor confidence.

SSY Group Gains Approval for New Antifungal Drug
Mar 21, 2025

SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of Voriconazole for Oral Suspension, a drug used to treat and prevent serious fungal infections. This development marks a significant step in SSY Group’s product offerings, potentially enhancing its market position and providing new treatment options for patients, particularly those undergoing high-risk medical procedures.

SSY Group’s Nimodipine Gains Approval for Market Entry
Mar 19, 2025

SSY Group Limited has announced that its product, Nimodipine, has received approval from the National Medical Products Administration of China to be marketed as a bulk drug. This development marks a significant step in the company’s product offerings, potentially enhancing its market position and providing new opportunities for growth in the pharmaceutical sector.

SSY Group to Announce Annual Results and Dividend Consideration
Mar 18, 2025

SSY Group Limited, a company incorporated in the Cayman Islands, has announced that its Board of Directors will meet on March 28, 2025, to approve the annual results for the year ending December 31, 2024, and to consider recommending a final dividend. This meeting is significant as it will determine the company’s financial performance and potential returns for shareholders, impacting its market positioning and stakeholder interests.

SSY Group Gains Approval for Key Drug Production
Mar 14, 2025

SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of Epinephrine Hydrochloride Injection, a critical drug for cardiopulmonary resuscitation and treatment of severe dyspnea and anaphylaxis. This development marks a significant step in the company’s product offerings, potentially enhancing its market position and providing stakeholders with an updated view of its business advancements.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.